致癌KRAS驱动脂成纤维化促进血管生成和结肠癌进展
本研究揭示致癌KRAS(KRAS*)通过激活转录因子CP2(TFCP2)上调BMP4和WNT5B,将癌相关成纤维细胞(CAF)转化为富脂CAF,进而产生VEGFA促进血管生成和肿瘤进展;在KRAS*驱动的结直肠癌小鼠模型中,遗传或药物中和TFCP2可减少富脂CAF、减轻肿瘤血管生成并改善总生存;人结直肠癌中富脂CAF和TFCP2特征与更差预后相关。
要点
- KRAS*通过TFCP2上调BMP4和WNT5B,驱动CAF转化为富脂CAF。
- 富脂CAF产生VEGFA促进血管生成,加速KRAS*驱动结直肠癌进展。
- 靶向KRAS*-TFCP2-VEGFA轴在临床前模型中改善生存,人结直肠癌中该特征与更差预后相关。
核心结论
- KRAS*通过将CAF转化为富脂CAF并产生VEGFA驱动肿瘤血管生成和疾病进展,靶向KRAS*-TFCP2-VEGFA轴在临床前模型中损害肿瘤进展,为KRAS*驱动结直肠癌患者揭示潜在新治疗选择。
研究设计与样本
- 临床前研究,使用KRAS*驱动的结直肠癌小鼠模型及人结直肠癌样本,未报告具体样本量。
主要发现
- KRAS*激活转录因子CP2(TFCP2),上调促脂肪生成因子BMP4和WNT5B表达,触发CAF转化为富脂CAF。
- 富脂CAF产生VEGFA以促进血管生成。
- 在KRAS*驱动的结直肠癌小鼠模型中,遗传或药物中和TFCP2减少富脂CAF、减轻肿瘤血管生成并改善总生存。
- 在人结直肠癌中,富脂CAF和TFCP2特征与更差预后相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Oncogenic KRAS (KRAS*) contributes to many cancer hallmarks. In colorectal cancer, KRAS* suppresses antitumor immunity to promote tumor invasion and metastasis. Here, we uncovered that KRAS* transforms the phenotype of carcinoma-associated fibroblasts (CAF) into lipid-laden CAFs, promoting angiogenesis and tumor progression. Mechanistically, KRAS* activates the transcription factor CP2 (TFCP2) that upregulates the expression of the proadipogenic factors BMP4 and WNT5B, triggering the transformation of CAFs into lipid-rich CAFs. These lipid-rich CAFs, in turn, produce VEGFA to spur angiogenesis. In KRAS*-driven colorectal cancer mouse models, genetic or pharmacologic neutralization of TFCP2 reduced lipid-rich CAFs, lessened tumor angiogenesis, and improved overall survival. Correspondingly, in human colorectal cancer, lipid-rich CAF and TFCP2 signatures correlate with worse prognosis. This work unveils a new role for KRAS* in transforming CAFs, driving tumor angiogenesis and disease progression, providing an actionable therapeutic intervention for KRAS*-driven colorectal cancer. SIGNIFICANCE: This study identified a molecular mechanism contributing to KRAS*-driven colorectal cancer progression via fibroblast transformation in the tumor microenvironment to produce VEGFA driving tumor angiogenesis. In preclinical models, targeting the KRAS*-TFCP2-VEGFA axis impaired tumor progression, revealing a potential novel therapeutic option for patients with KRAS*-driven colorectal cancer. This article is featured in Selected Articles from This Issue, p. 2489.
引用
- Hsu WH, LaBella KA, Lin Y, et al. Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression. Cancer Discov. 2023. PMID: 37768068. doi:10.1158/2159-8290.CD-22-1467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。